ADX-097 for Immunoglobulin A Nephropathy
What You Need to Know Before You Apply
What is the purpose of this trial?
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
Will I have to stop taking my current medications?
The trial requires that if you are taking a RAAS inhibitor or a sodium-glucose cotransporter-2 (SGLT2) inhibitor, you must have been on a stable dose for at least 12 weeks before starting the study and continue on that stable dose during the study.
What data supports the effectiveness of the drug ADX-097 for treating Immunoglobulin A Nephropathy?
Research on similar treatments, like steroids, shows they can lower the risk of kidney disease progression and reduce protein in urine for patients with Immunoglobulin A Nephropathy. This suggests that immunosuppressive agents, which may include ADX-097, could be promising for treating this condition.12345
Are You a Good Fit for This Trial?
This trial is for adults over 18 with certain kidney conditions: IgAN, LN, or C3G. They should have protein in their urine and a minimum kidney function level. Participants must be on stable doses of specific medications for at least 12 weeks before the study starts.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive subcutaneous infusions of ADX-097
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ADX-097
Find a Clinic Near You
Who Is Running the Clinical Trial?
Q32 Bio Inc.
Lead Sponsor